BACKGROUND: Gut dysbiosis associated with the use of proton-pump inhibitors (PPIs) has been found to lead to the occurrence of infectious and inflammatory adverse events. A longitudinal observational cohort study has demonstrated the heightened risk of death associated with PPI use. SUMMARY: We evaluated meta-analyses to determine the association between PPI use and infectious and inflammatory diseases. Meta-analyses showed that PPI use is a potential risk for the development of enteric infections caused by Clostridium difficile, as well as small intestinal bacterial overgrowth, spontaneous bacterial peritonitis, community-acquired pneumonia, hepatic encephalopathy, and adverse outcomes in inflammatory bowel disease. We also examined changes in the composition and function of the gut microbiota with the use of PPIs. PPI use significantly increased the presence of Streptococcaceae and Enterococcaceae, which are risk factors for C. difficile infection, and decreased that of Faecalibacterium, a commensal anti-inflammatory microorganism. Key Message: High-throughput, microbial 16S rRNA gene sequencing has allowed us to investigate the association between the gut microbiome and PPI use. Future prospective comparison studies are necessary to confirm this association, and to develop new strategies to prevent complications of PPI use.
BACKGROUND: Gut dysbiosis associated with the use of proton-pump inhibitors (PPIs) has been found to lead to the occurrence of infectious and inflammatory adverse events. A longitudinal observational cohort study has demonstrated the heightened risk of death associated with PPI use. SUMMARY: We evaluated meta-analyses to determine the association between PPI use and infectious and inflammatory diseases. Meta-analyses showed that PPI use is a potential risk for the development of enteric infections caused by Clostridium difficile, as well as small intestinal bacterial overgrowth, spontaneous bacterial peritonitis, community-acquired pneumonia, hepatic encephalopathy, and adverse outcomes in inflammatory bowel disease. We also examined changes in the composition and function of the gut microbiota with the use of PPIs. PPI use significantly increased the presence of Streptococcaceae and Enterococcaceae, which are risk factors for C. difficile infection, and decreased that of Faecalibacterium, a commensal anti-inflammatory microorganism. Key Message: High-throughput, microbial 16S rRNA gene sequencing has allowed us to investigate the association between the gut microbiome and PPI use. Future prospective comparison studies are necessary to confirm this association, and to develop new strategies to prevent complications of PPI use.
Authors: Jinqiu Yuan; Changhua Zhang; Jeffrey A Sparks; Susan Malspeis; Kelvin Kam-Fai Tsoi; Jean H Kim; Benjamin A Fisher; Fang Gao; Tim Sumerlin; Yan Liu; Yuxing Liu; Yihang Pan; Yulong He; Joseph J Y Sung Journal: Aliment Pharmacol Ther Date: 2020-06-29 Impact factor: 8.171
Authors: Daniel R Duncan; Paul D Mitchell; Kara Larson; Maireade E McSweeney; Rachel L Rosen Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: Naomi R M Schwartz; Susan Hutfless; Lisa J Herrinton; Laura B Amsden; Helene B Fevrier; Matthew Giefer; Dale Lee; David L Suskind; Joseph A C Delaney; Amanda I Phipps Journal: J Pediatr Pharmacol Ther Date: 2019 Nov-Dec
Authors: Karolina Skonieczna-Żydecka; Ewa Stachowska; Dominika Maciejewska; Karina Ryterska; Joanna Palma; Maja Czerwińska-Rogowska; Mariusz Kaczmarczyk; Anna Gudan; Honorata Mruk; Barbara Świniarska; Justyna Kałduńska; Zofia Stachowska; Przemysław Mijal; Tomasz Mazur; Maciej Kupczyński; Wojciech Marlicz Journal: Int J Environ Res Public Health Date: 2018-10-15 Impact factor: 3.390
Authors: Óskar Ö Hálfdánarson; Anton Pottegård; Einar S Björnsson; Sigrún H Lund; Margret H Ogmundsdottir; Eiríkur Steingrímsson; Helga M Ogmundsdottir; Helga Zoega Journal: Therap Adv Gastroenterol Date: 2018-05-30 Impact factor: 4.409